|
1
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Islami F, Torre LA and Jemal A: Global
trends of lung cancer mortality and smoking prevalence. Transl Lung
Cancer Res. 4:327–338. 2015.PubMed/NCBI
|
|
4
|
Subramanian J and Govindan R: Lung cancer
in never smokers: A review. J Clin Oncol. 25:561–570. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Wang DC, Shi L, Zhu B, Min Z and
Jin J: Genome analyses identify the genetic modification of lung
cancer subtypes. Semin Cancer Biol. 42:20–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sittka A and Schmeck B: MicroRNAs in the
lung. Adv Exp Med Biol. 774:121–134. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ke Y, Zhao W, Xiong J and Cao R:
Downregulation of miR-16 promotes growth and motility by targeting
HDGF in non-small cell lung cancer cells. FEBS Lett. 587:3153–3157.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han H, Yang J, Wang Y, Chen W, Chen J,
Yang Y and Li Q: Nucleobase-modified polyamidoamine-mediated
miR-23b delivery to inhibit the proliferation and migration of lung
cancer. Biomater Sci. 5:2268–2275. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma Q, Jiang Q, Pu Q, Zhang X, Yang W, Wang
Y, Ye S, Wu S, Zhong G, Ren J, et al: MicroRNA-143 inhibits
migration and invasion of human non-small-cell lung cancer and its
relative mechanism. Int J Biol Sci. 9:680–692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu S, Witmer PD, Lumayag S, Kovacs B and
Valle D: MicroRNA (miRNA) transcriptome of mouse retina and
identification of a sensory organ-specific miRNA cluster. J Biol
Chem. 282:25053–25066. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hong Y, Liang H, Uzair-Ur-Rehman, Wang Y,
Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, et al: miR-96 promotes
cell proliferation, migration and invasion by targeting PTPN9 in
breast cancer. Sci Rep. 6:374212016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ress AL, Stiegelbauer V, Winter E,
Schwarzenbacher D, Kiesslich T, Lax S, Jahn S, Deutsch A,
Bauernhofer T, Ling H, et al: MiR-96-5p influences cellular growth
and is associated with poor survival in colorectal cancer patients.
Mol Carcinog. 54:1442–1450. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu L, Pu X, Wang Q, Cao J, Xu F, Xu LI and
Li K: miR-96 induces cisplatin chemoresistance in non-small cell
lung cancer cells by downregulating SAMD9. Oncol Lett. 11:945–952.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo H, Li Q, Li W, Zheng T, Zhao S and Liu
Z: MiR-96 downregulates RECK to promote growth and motility of
non-small cell lung cancer cells. Mol Cell Biochem. 390:155–160.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jalvy-Delvaille S, Maurel M, Majo V,
Pierre N, Chabas S, Combe C, Rosenbaum J, Sagliocco F and Grosset
CF: Molecular basis of differential target regulation by miR-96 and
miR-182: The Glypican-3 as a model. Nucleic Acids Res.
40:1356–1365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai Z, Grobe K and Zhang X: Role of
heparan sulfate proteoglycans in optic disc and stalk
morphogenesis. Dev Dyn. 243:1310–1316. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bernfield M, Götte M, Park PW, Reizes O,
Fitzgerald ML, Lincecum J and Zako M: Functions of cell surface
heparan sulfate proteoglycans. Annu Rev Biochem. 68:729–777. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Murthy SS, Shen T, De Rienzo A, Lee WC,
Ferriola PC, Jhanwar SC, Mossman BT, Filmus J and Testa JR:
Expression of GPC3, an X-linked recessive overgrowth gene, is
silenced in malignant mesothelioma. Oncogene. 19:410–416. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
White GR, Kelsey AM, Varley JM and Birch
JM: Somatic glypican 3 (GPC3) mutations in Wilms' tumour. Br J
Cancer. 86:1920–1922. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Filmus J: Glypicans in growth control and
cancer. Glycobiology. 11:19R–23R. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ho M and Kim H: Glypican-3: A new target
for cancer immunotherapy. Eur J Cancer. 47:333–338. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li L, Jin R, Zhang X, Lv F, Liu L, Liu D,
Liu K, Li N and Chen D: Oncogenic activation of glypican-3 by c-Myc
in human hepatocellular carcinoma. Hepatology. 56:1380–1390. 2012.
View Article : Google Scholar : PubMed/NCBI
|
